Scholarlink

Purpose <p>To assess the reliability of <i>en face</i> swept-source OCT (SS-OCT) imaging for quantifying macular atrophy in patients with neovascular age-related macular degeneration (AMD) and evaluate its limitations compared to green autofluorescence (GAF) imaging.</p> Methods <p>This prospective observational study included 30 patients with macular atrophy associated with neovascular AMD previously treated with anti-VEGF therapy. Multimodal imaging included GAF and <i>en face</i> SS-OCT. Macular atrophy was quantified as regions of hypoautofluorescence on GAF and hypertransmission defects (hyperTDs) on <i>en face</i> SS-OCT. Two masked graders measured atrophy size, followed by qualitative analysis of inter-modality discrepancies. Statistical comparisons were conducted using the Wilcoxon test and Spearman correlation.</p> Results <p>Mean macular atrophy size was 5.96 ± 4.48 mm² on SS-OCT and 7.10 ± 5.47 mm² on GAF, with a significant difference (<i>p</i> &lt; 0.001) but strong correlation (ρ = 0.998, <i>p</i> &lt; 0.001). Discrepancies arose due to hyperpigmentation obscuring hyperTDs and macular haemorrhages on SS-OCT underestimations of atrophy. Additionally, fibrosis also reduced choroidal hypertransmission, complicating hyperTD detection on SS-OCT. Border delineation inconsistencies were also observed, with diminished autofluorescence on GAF not always corresponding to hyperTDs on SS-OCT.</p> Conclusions <p><i>En face</i> SS-OCT is a reliable imaging modality for quantifying macular atrophy in neovascular AMD, with strong correlation to GAF measurements. However, hyperpigmentation, fibrosis, haemorrhages, and variability in border delineation introduce significant challenges. These findings underscore the need for careful interpretation of atrophy metrics and highlight the importance of addressing inter-modality discrepancies in clinical and research applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Quantifying macular atrophy in neovascular AMD using en face structural OCT imaging

  • 期刊论文

  • 发表日期：

    2025年7月9日

查看全文
  • Chiara Olivieri,
  • Tommaso Tibaldi,
  • Alessandro Berni,
  • Chiara Maria Eandi,
  • Giovanni Neri,
  • Antonio Fai,
  • Pasquale Viggiano,
  • Paola Marolo,
  • Francesco Bandello,
  • Michele Reibaldi,
  • Enrico Borrelli

摘要

Purpose

To assess the reliability of en face swept-source OCT (SS-OCT) imaging for quantifying macular atrophy in patients with neovascular age-related macular degeneration (AMD) and evaluate its limitations compared to green autofluorescence (GAF) imaging.

Methods

This prospective observational study included 30 patients with macular atrophy associated with neovascular AMD previously treated with anti-VEGF therapy. Multimodal imaging included GAF and en face SS-OCT. Macular atrophy was quantified as regions of hypoautofluorescence on GAF and hypertransmission defects (hyperTDs) on en face SS-OCT. Two masked graders measured atrophy size, followed by qualitative analysis of inter-modality discrepancies. Statistical comparisons were conducted using the Wilcoxon test and Spearman correlation.

Results

Mean macular atrophy size was 5.96 ± 4.48 mm² on SS-OCT and 7.10 ± 5.47 mm² on GAF, with a significant difference (p < 0.001) but strong correlation (ρ = 0.998, p < 0.001). Discrepancies arose due to hyperpigmentation obscuring hyperTDs and macular haemorrhages on SS-OCT underestimations of atrophy. Additionally, fibrosis also reduced choroidal hypertransmission, complicating hyperTD detection on SS-OCT. Border delineation inconsistencies were also observed, with diminished autofluorescence on GAF not always corresponding to hyperTDs on SS-OCT.

Conclusions

En face SS-OCT is a reliable imaging modality for quantifying macular atrophy in neovascular AMD, with strong correlation to GAF measurements. However, hyperpigmentation, fibrosis, haemorrhages, and variability in border delineation introduce significant challenges. These findings underscore the need for careful interpretation of atrophy metrics and highlight the importance of addressing inter-modality discrepancies in clinical and research applications.